Alnylam Announces U.S. Food and Drug Administration …
1 day ago · CAMBRIDGE, Mass., November 25, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Press Releases - Alnylam Pharmaceuticals, Inc.
Oct 9, 2024 · Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Sep 29, 2024 Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society ...
FDA Begins Review of Alnylam's sNDA for Expanded …
19 hours ago · Amvuttra sales contribute significantly to Alnylam’s top line. The drug generated sales worth $693.9 million in the nine months ended Sept. 30, 2024, up 79% on a reported basis.
Alnylam Pharmaceuticals Press Release | Nov 25, 2024 | Alnylam ...
2 days ago · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM …
2 days ago · Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company’s supplemental New Drug Application sNDA for vutrisiran, an ...
Alnylam Submits Supplemental New Drug Application …
CAMBRIDGE, Mass., October 09, 2024 -- (BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New...
Alnylam® Newsroom
Visit our social channels to learn more about the innovative work we are doing at Alnylam.
Alnylam Shares Surge 30% After Rare Heart Disease Drug Success - Forbes
Jun 24, 2024 · Alnylam said Monday that vutrisiran, an experimental drug for treating a rare condition called transthyretin amyloid cardiomyopathy (ATTR-CM), reduced deaths by all causes and heart-related...
Alnylam's drug cuts risk of death, heart issues in key study, …
June 24 (Reuters) - Alnylam Pharmaceuticals (ALNY.O) said its drug vutrisiran reduced deaths and cardiovascular events by a third in a study involving patients with a rare heart disease, sending...
Taking RNAi from interesting science to impactful new …
May 13, 2024 · Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.